Join Growin Stock Community!

Immatics n.v.IMTX.US Overview

US StockHealthcare
(No presentation for IMTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IMTX AI Insights

IMTX Overall Performance

IMTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IMTX Recent Performance

-0.87%

Immatics n.v.

0.05%

Avg of Sector

-0.31%

S&P500

IMTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IMTX Key Information

IMTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IMTX Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Price of IMTX

IMTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IMTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.86
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
16.36
PB Ratio
2.77
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-136.72%
Revenue Growth (YoY)
-26.62%
Profit Growth (YoY)
-26.62%
3-Year Revenue Growth
-29.90%
3-Year Profit Growth
-29.90%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.86
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
16.36
PB Ratio
2.77
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-136.72%
Revenue Growth (YoY)
-26.62%
Profit Growth (YoY)
-26.62%
3-Year Revenue Growth
-29.90%
3-Year Profit Growth
-29.90%

  • When is IMTX's latest earnings report released?

    The most recent financial report for Immatics n.v. (IMTX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IMTX's short-term business performance and financial health. For the latest updates on IMTX's earnings releases, visit this page regularly.

  • What is the operating profit of IMTX?

    According to the latest financial report, Immatics n.v. (IMTX) reported an Operating Profit of -54.63M with an Operating Margin of -1,053.27% this period, representing a decline of 10,728.99% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IMTX's revenue growth?

    In the latest financial report, Immatics n.v. (IMTX) announced revenue of 5.19M, with a Year-Over-Year growth rate of -89.74%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does IMTX have?

    As of the end of the reporting period, Immatics n.v. (IMTX) had total debt of 16.38M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IMTX have?

    At the end of the period, Immatics n.v. (IMTX) held Total Cash and Cash Equivalents of 334.92M, accounting for 0.65 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does IMTX go with three margins increasing?

    In the latest report, Immatics n.v. (IMTX) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -1,053.27%%, and net margin of -974.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IMTX's profit trajectory and future growth potential.

  • Is IMTX's EPS continuing to grow?

    According to the past four quarterly reports, Immatics n.v. (IMTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.42. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IMTX?

    Immatics n.v. (IMTX)'s Free Cash Flow (FCF) for the period is -45.79M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 25.34% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of IMTX?

    The latest valuation data shows Immatics n.v. (IMTX) has a Price-To-Earnings (PE) ratio of -8.54 and a Price/Earnings-To-Growth (PEG) ratio of 0.16. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.